{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:38Z","timestamp":1793120078121,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Association with hypomethylating agents is a promising strategy to improve the efficacy of immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation trial in patients with advanced melanoma of the hypomethylating agent guadecitabine combined with the anti-CTLA-4 antibody ipilimumab that followed a traditional 3\u2009+\u20093 design (NCT02608437). Patients received guadecitabine 30, 45 or 60\u2009mg\/m<jats:sup>2<\/jats:sup>\/day subcutaneously on days 1 to 5 every 3 weeks starting on week 0 for a total of four cycles, and ipilimumab 3\u2009mg\/kg intravenously starting on day 1 of week 1 every 3 weeks for a total of four cycles. Primary outcomes of safety, tolerability, and maximum tolerated dose of treatment were previously reported. Here we report the 5-year clinical outcome for the secondary endpoints of overall survival, progression free survival, and duration of response, and an exploratory integrated multi-omics analysis on pre- and on-treatment tumor biopsies. With a minimum follow-up of 45 months, the 5-year overall survival rate was 28.9% and the median duration of response was 20.6 months. Re-expression of immuno-modulatory endogenous retroviruses and of other repetitive elements, and a mechanistic signature of guadecitabine are associated with response. Integration of a genetic immunoediting index with an adaptive immunity signature stratifies patients\/lesions into four distinct subsets and discriminates 5-year overall survival and progression free survival. These results suggest that coupling genetic immunoediting with activation of adaptive immunity is a relevant requisite for achieving long term clinical benefit by epigenetic immunomodulation in advanced melanoma patients.<\/jats:p>","DOI":"10.1038\/s41467-023-40994-4","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T12:02:23Z","timestamp":1695384143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6752","authenticated-orcid":false,"given":"Teresa Maria Rosaria","family":"Noviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-1459","authenticated-orcid":false,"given":"Francesca Pia","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Covre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Mortarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-7220","authenticated-orcid":false,"given":"Maria Claudia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Coral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-0973","authenticated-orcid":false,"given":"Wolf H.","family":"Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1735-8722","authenticated-orcid":false,"given":"Catherine","family":"Saut\u00e8s-Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Brich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fortunata","family":"Lofiego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5857-773X","authenticated-orcid":false,"given":"Davide","family":"Bedognetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5538","authenticated-orcid":false,"given":"Andrea","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-6321","authenticated-orcid":false,"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"40994_CR1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56\u201361 (2015).","journal-title":"Science"},{"key":"40994_CR2","doi-asserted-by":"crossref","first-page":"e2012534","DOI":"10.1001\/jamanetworkopen.2020.12534","volume":"3","author":"F Yang","year":"2020","unstructured":"Yang, F. et al. Association of sex, age, and eastern cooperative oncology group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: a systematic review and meta-analysis. JAMA Netw. Open 3, e2012534 (2020).","journal-title":"JAMA Netw. Open"},{"key":"40994_CR3","doi-asserted-by":"crossref","unstructured":"Bhave, P. et al. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. J. Immunother. Cancer 10, e004668 (2022).","DOI":"10.1136\/jitc-2022-004668"},{"key":"40994_CR4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares, L. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929\u20131939 (2019).","journal-title":"Lancet"},{"key":"40994_CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"40994_CR6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"40994_CR7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"40994_CR8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41416-020-01145-4","volume":"124","author":"T Turan","year":"2021","unstructured":"Turan, T. et al. A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. Br. J. Cancer 124, 760\u2013769 (2021).","journal-title":"Br. J. Cancer"},{"key":"40994_CR9","doi-asserted-by":"crossref","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","DOI":"10.1126\/science.aar3593"},{"key":"40994_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13046-022-02529-5","volume":"41","author":"A Anichini","year":"2022","unstructured":"Anichini, A. et al. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. J. Exp. Clin. Cancer Res. 41, 325 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"40994_CR11","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1158\/1078-0432.CCR-19-1335","volume":"25","author":"AM Di Giacomo","year":"2019","unstructured":"Di Giacomo, A. M. et al. Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial. Clin. Cancer Res. 25, 7351\u20137362 (2019).","journal-title":"Clin. Cancer Res."},{"key":"40994_CR12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961\u2013973 (2015).","journal-title":"Cell"},{"key":"40994_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","volume":"19","author":"PA Jones","year":"2019","unstructured":"Jones, P. A., Ohtani, H., Chakravarthy, A. & De Carvalho, D. D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 19, 151\u2013161 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"40994_CR14","doi-asserted-by":"crossref","unstructured":"Chen, S. et al. Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J. Clin. Invest. 132, e158800 (2022).","DOI":"10.1172\/JCI158800"},{"key":"40994_CR15","doi-asserted-by":"crossref","unstructured":"Papadatos-Pastos, D. et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J. Immunother. Cancer 10, e004495 (2022).","DOI":"10.1136\/jitc-2022-004495"},{"key":"40994_CR16","doi-asserted-by":"crossref","unstructured":"Roelands, J. et al. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. J. Immunother. Cancer 8, e000617 (2020).","DOI":"10.1136\/jitc-2020-000617"},{"key":"40994_CR17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41591-023-02324-5","volume":"29","author":"J Roelands","year":"2023","unstructured":"Roelands, J. et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat. Med. 29, 1273\u20131286 (2023).","journal-title":"Nat. Med."},{"key":"40994_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","volume":"39","author":"J Galon","year":"2013","unstructured":"Galon, J., Angell, H. K., Bedognetti, D. & Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11\u201326 (2013).","journal-title":"Immunity"},{"key":"40994_CR19","doi-asserted-by":"crossref","first-page":"e1253654","DOI":"10.1080\/2162402X.2016.1253654","volume":"6","author":"W Hendrickx","year":"2017","unstructured":"Hendrickx, W. et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology 6, e1253654 (2017).","journal-title":"Oncoimmunology"},{"key":"40994_CR20","doi-asserted-by":"crossref","unstructured":"Bertucci, F. et al. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. J. Immunother. Cancer 10, e003687 (2022).","DOI":"10.1136\/jitc-2021-003687"},{"key":"40994_CR21","volume":"5","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. NPJ Precis. Oncol. 5, 56 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"40994_CR22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","volume":"3","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B. et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol. Res. 3, 288\u2013295 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"40994_CR23","doi-asserted-by":"crossref","first-page":"e0139438","DOI":"10.1371\/journal.pone.0139438","volume":"10","author":"J Mangana","year":"2015","unstructured":"Mangana, J. et al. Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival? PLoS One 10, e0139438 (2015).","journal-title":"PLoS One"},{"key":"40994_CR24","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib, E. et al. CDKN2A alterations and response to immunotherapy in solid tumors. Clin. Cancer Res. 27, 4025\u20134035 (2021).","journal-title":"Clin. Cancer Res."},{"key":"40994_CR25","volume":"19","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. BMC Med. 19, 26 (2021).","journal-title":"BMC Med."},{"key":"40994_CR26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/2326-6066.CIR-21-0061","volume":"10","author":"W Celus","year":"2022","unstructured":"Celus, W. et al. Plexin-A4 mediates cytotoxic T-cell trafficking and exclusion in cancer. Cancer Immunol. Res. 10, 126\u2013141 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"40994_CR27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/pcmedi\/pbz006","volume":"2","author":"M Wang","year":"2019","unstructured":"Wang, M., Yu, L., Wei, X. & Wei, Y. Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precis. Clin. Med. 2, 100\u2013109 (2019).","journal-title":"Precis. Clin. Med."},{"key":"40994_CR28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","volume":"616","author":"KW Ng","year":"2023","unstructured":"Ng, K. W. et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature 616, 563\u2013573 (2023).","journal-title":"Nature"},{"key":"40994_CR29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tcb.2018.07.006","volume":"29","author":"H Loo Yau","year":"2019","unstructured":"Loo Yau, H., Ettayebi, I. & De Carvalho, D. D. The cancer epigenome: exploiting its vulnerabilities for immunotherapy. Trends Cell Biol. 29, 31\u201343 (2019).","journal-title":"Trends Cell Biol."},{"key":"40994_CR30","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1158\/2159-8290.CD-21-0506","volume":"11","author":"R Chen","year":"2021","unstructured":"Chen, R., Ishak, C. A. & De Carvalho, D. D. Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis. Cancer Discov. 11, 2707\u20132725 (2021).","journal-title":"Cancer Discov."},{"key":"40994_CR31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"40994_CR32","doi-asserted-by":"crossref","first-page":"e223833","DOI":"10.1001\/jamanetworkopen.2022.3833","volume":"5","author":"DA Mata","year":"2022","unstructured":"Mata, D. A. et al. Prevalence of UV mutational signatures among cutaneous primary tumors. JAMA Netw. Open 5, e223833 (2022).","journal-title":"JAMA Netw. Open"},{"key":"40994_CR33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545\u20131549 (2018).","journal-title":"Nat. Med."},{"key":"40994_CR34","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui, C. et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 184, 6101\u20136118.e13 (2021).","journal-title":"Cell"},{"key":"40994_CR35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41591-020-0818-3","volume":"26","author":"E P\u00e9rez-Guijarro","year":"2020","unstructured":"P\u00e9rez-Guijarro, E. et al. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nat. Med. 26, 781\u2013791 (2020).","journal-title":"Nat. Med."},{"key":"40994_CR36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","volume":"40","author":"NS Patil","year":"2022","unstructured":"Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 40, 289\u2013300.e4 (2022).","journal-title":"Cancer Cell"},{"key":"40994_CR37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"40994_CR38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541.e5 (2022).","journal-title":"Immunity"},{"key":"40994_CR39","doi-asserted-by":"crossref","first-page":"abe6474","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"40994_CR40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir, A. et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40, 318\u2013334.e9 (2022).","journal-title":"Cancer Cell"},{"key":"40994_CR41","doi-asserted-by":"crossref","unstructured":"Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, eaar3342 (2018).","DOI":"10.1126\/scitranslmed.aar3342"},{"key":"40994_CR42","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"40994_CR43","doi-asserted-by":"crossref","first-page":"e1019978","DOI":"10.1080\/2162402X.2015.1019978","volume":"4","author":"A Covre","year":"2015","unstructured":"Covre, A. et al. Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. Oncoimmunology 4, e1019978 (2015).","journal-title":"Oncoimmunology"},{"key":"40994_CR44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/35020115","volume":"406","author":"M Bittner","year":"2000","unstructured":"Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536\u2013540 (2000).","journal-title":"Nature"},{"key":"40994_CR45","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"40994_CR46","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-017-1477-3","volume":"18","author":"NA Wijetunga","year":"2017","unstructured":"Wijetunga, N. A. et al. SMITE: an R\/Bioconductor package that identifies network modules by integrating genomic and epigenomic information. BMC Bioinformatics 18, 41 (2017).","journal-title":"BMC Bioinformatics"},{"key":"40994_CR47","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"40994_CR48","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"40994_CR49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"40994_CR50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1415938","volume":"372","author":"A Snyder","year":"2015","unstructured":"Snyder, A., Wolchok, J. D. & Chan, T. A. Genetic basis for clinical response to CTLA-4 blockade. N. Engl. J. Med. 372, 783 (2015).","journal-title":"N. Engl. J. Med."},{"key":"40994_CR51","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","volume":"168","author":"W Hugo","year":"2017","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 168, 542 (2017).","journal-title":"Cell"},{"key":"40994_CR52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127\u2013137 (2022).","journal-title":"J. Clin. Oncol."},{"key":"40994_CR53","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 1, 433\u2013440 (2015).","journal-title":"JAMA Oncol."},{"key":"40994_CR54","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1097\/IJ9.0000000000000043","volume":"2","author":"K Rossfeld","year":"2017","unstructured":"Rossfeld, K. et al. Metastatic melanoma patients\u2019 sensitivity to ipilimumab cannot be predicted by tumor characteristics. Int. J. Surg. Oncol. 2, e43 (2017).","journal-title":"Int. J. Surg. Oncol."},{"key":"40994_CR55","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jnci\/djx271","volume":"110","author":"S Horn","year":"2018","unstructured":"Horn, S. et al. Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance. J. Natl Cancer Inst. 110, 677\u2013681 (2018).","journal-title":"J. Natl Cancer Inst."},{"key":"40994_CR56","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"40994_CR57","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","volume":"22","author":"Y Lou","year":"2016","unstructured":"Lou, Y. et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 22, 3630\u20133642 (2016).","journal-title":"Clin. Cancer Res."},{"key":"40994_CR58","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/0008-5472.CAN-12-0653","volume":"73","author":"JM Low-Marchelli","year":"2013","unstructured":"Low-Marchelli, J. M. et al. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 73, 662\u2013671 (2013).","journal-title":"Cancer Res."},{"key":"40994_CR59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"40994_CR60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41588-023-01349-3","volume":"55","author":"NM Shah","year":"2023","unstructured":"Shah, N. M. et al. Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. Nat. Genet. 55, 631\u2013639 (2023).","journal-title":"Nat. Genet."},{"key":"40994_CR61","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41416-018-0309-1","volume":"119","author":"F Bertucci","year":"2018","unstructured":"Bertucci, F. et al. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Br. J. Cancer 119, 1383\u20131391 (2018).","journal-title":"Br. J. Cancer"},{"key":"40994_CR62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","volume":"175","author":"M Angelova","year":"2018","unstructured":"Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751\u2013765.e16 (2018).","journal-title":"Cell"},{"key":"40994_CR63","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen, S. P., L\u00f6ffler, M. W., Rammensee, H.-G. & Brossart, P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595\u2013610 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"40994_CR64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","volume":"31","author":"JS Blum","year":"2013","unstructured":"Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of antigen processing. Annu. Rev. Immunol. 31, 443\u2013473 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"40994_CR65","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"40994_CR66","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"40994_CR67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"40994_CR68","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3389\/fgene.2019.00736","volume":"10","author":"KI Kendig","year":"2019","unstructured":"Kendig, K. I. et al. Sentieon dnaseq variant calling workflow demonstrates strong computational performance and accuracy. Front. Genet. 10, 736 (2019).","journal-title":"Front. Genet."},{"key":"40994_CR69","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1101\/gr.183053.114","volume":"25","author":"S Hiltemann","year":"2015","unstructured":"Hiltemann, S., Jenster, G., Trapman, J., van der Spek, P. & Stubbs, A. Discriminating somatic and germline mutations in tumor DNA samples without matching normals. Genome Res. 25, 1382\u20131390 (2015).","journal-title":"Genome Res."},{"key":"40994_CR70","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"40994_CR71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"},{"key":"40994_CR72","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248\u2013249 (2010).","journal-title":"Nat. Methods"},{"key":"40994_CR73","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1101\/gr.176601","volume":"11","author":"CN Pauline","year":"2001","unstructured":"Pauline, C. N. & Henikoff, S. Predicting deleterious amino acid substitutions. Genome Res. 11, 863\u2013874 (2001).","journal-title":"Genome Res."},{"key":"40994_CR74","doi-asserted-by":"crossref","first-page":"e46688","DOI":"10.1371\/journal.pone.0046688","volume":"7","author":"Y Choi","year":"2012","unstructured":"Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect of amino acid substitutions and indels. PLoS One 7, e46688 (2012).","journal-title":"PLoS One"},{"key":"40994_CR75","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"40994_CR76","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"40994_CR77","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"40994_CR78","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"40994_CR79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"40994_CR80","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"40994_CR81","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-12-480","volume":"12","author":"D Risso","year":"2011","unstructured":"Risso, D., Schwartz, K., Sherlock, G. & Dudoit, S. GC-content normalization for RNA-Seq data. BMC Bioinformatics 12, 480 (2011).","journal-title":"BMC Bioinformatics"},{"key":"40994_CR82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"40994_CR83","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"40994_CR84","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"40994_CR85","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/bioinformatics\/btr167","volume":"27","author":"F Krueger","year":"2011","unstructured":"Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for bisulfite-seq applications. Bioinformatics 27, 1571\u20131572 (2011).","journal-title":"Bioinformatics"},{"key":"40994_CR86","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1664-9","volume":"20","author":"F M\u00fcller","year":"2019","unstructured":"M\u00fcller, F. et al. RnBeads 2.0: comprehensive analysis of DNA methylation data. Genome Biol. 20, 55 (2019).","journal-title":"Genome Biol."},{"key":"40994_CR87","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"40994_CR88","doi-asserted-by":"crossref","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","volume":"9","author":"M Lawrence","year":"2013","unstructured":"Lawrence, M. et al. Software for computing and annotating genomic ranges. PLoS Comput. Biol. 9, e1003118 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"40994_CR89","doi-asserted-by":"crossref","first-page":"bax028","DOI":"10.1093\/database\/bax028","volume":"2017","author":"S Fishilevich","year":"2017","unstructured":"Fishilevich, S. et al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database 2017, bax028 (2017).","journal-title":"Database"},{"key":"40994_CR90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature23451","volume":"548","author":"J Joung","year":"2017","unstructured":"Joung, J. et al. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature 548, 343\u2013346 (2017).","journal-title":"Nature"},{"key":"40994_CR91","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cels.2019.04.001","volume":"8","author":"EM Liu","year":"2019","unstructured":"Liu, E. M. et al. Identification of cancer drivers at CTCF insulators in 1,962 whole genomes. Cell Syst. 8, 446\u2013455.e8 (2019).","journal-title":"Cell Syst."},{"key":"40994_CR92","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature25171","volume":"553","author":"V Frattini","year":"2018","unstructured":"Frattini, V. et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer. Nature 553, 222\u2013227 (2018).","journal-title":"Nature"},{"key":"40994_CR93","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu, J. et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 12, 21 (2020).","journal-title":"Genome Med."},{"key":"40994_CR94","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"40994_CR95","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/s41591-018-0247-8","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1942 (2018).","journal-title":"Nat. Med."},{"key":"40994_CR96","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"40994_CR97","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152\u20131158 (2015).","journal-title":"Nat. Biotechnol."},{"key":"40994_CR98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal, J. et al. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol. Res. 8, 409\u2013420 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"40994_CR99","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s42003-019-0369-7","volume":"2","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. Commun. Biol. 2, 135 (2019).","journal-title":"Commun. Biol."},{"key":"40994_CR100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40994-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40994-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T03:15:53Z","timestamp":1700190953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40994-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40994"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-40994-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.D.G. has served as consultant and\/or advisor to Incyte, Pierre Fabre, Glaxo Smith Kline, Bristol-Myers Squibb, Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol-Myers Squibb, Merck Sharp Dohme, Pierre Fabre, and Sanofi. W.H.F. has served as consultant and\/or advisor to AstraZeneca, Adaptimmune, Catalym, OOSE Immunotherapeutics, and Novartis, and reports receiving speakers bureau honoraria from Bristol-Myers Squibb. MM has served as consultant and\/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, Glaxo Smith Kline, Sciclone, Sanofi, Alfasigma, and Merck Serono; and own shares in Theravance and Epigen Therapeutics, Srl. MC serves as consultant and\/or advisor to Moderna Therapeutics and is the founder and owns shares of Immunomica srl. Other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5914"}}